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Abstract
Background: Although paediatric high grade gliomas resemble their adult counterparts in many ways, there appear to be
distinct clinical and biological differences. One important factor hampering the development of new targeted therapies is
the relative lack of cell lines derived from childhood glioma patients, as it is unclear whether the well-established adult lines
commonly used are representative of the underlying molecular genetics of childhood tumours. We have carried out a
detailed molecular and phenotypic characterisation of a series of paediatric high grade glioma cell lines in comparison to
routinely used adult lines.
Principal Findings: All lines proliferate as adherent monolayers and express glial markers. Copy number profiling revealed
complex genomes including amplification and deletions of genes known to be pivotal in core glioblastoma signalling
pathways. Expression profiling identified 93 differentially expressed genes which were able to distinguish between the adult
and paediatric high grade cell lines, including a number of kinases and co-ordinated sets of genes associated with DNA
integrity and the immune response.
Significance: These data demonstrate that glioma cell lines derived from paediatric patients show key molecular differences
to those from adults, some of which are well known, whilst others may provide novel targets for evaluation in primary
tumours. We thus provide the rationale and demonstrate the practicability of using paediatric glioma cell lines for preclinical
and mechanistic studies.
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Introduction
Paediatric high grade glioma is a clinically devastating and
biologically under-studied cancer of the central nervous system.
The poor clinical outcome of these children is largely due to the
intrinsic drug resistance of these tumours coupled with a lack of
understanding of the basic molecular pathology of the disease [1].
Unlike adults, little is known about the mechanisms of
tumorigenesis of glioblastoma in children. TP53 mutation and
PDGFRa overexpression, alterations associated with secondary
glioblastoma in adults, have been reported at high frequencies in
paediatric cases, [2], however these tumours rarely originate from
pre-existing low grade lesions [3]. Furthermore, although there are
clear morphological similarities between high grade gliomas of all
ages, the WHO classification system is based upon adult cases, and
may not be truly representative of the histopathological diversity of
the childhood disease [4]. Firm conclusions are hampered by the
limited number of studies performed on small sample sizes.
Drug treatment efficacy also differs. In adult glioblastoma,
introduction of combined chemoradiotherapy of concomitant and
adjuvant temozolomide (TMZ) and radiotherapy has provided a
modest survival benefit [5], particularly in patients with an
epigenetically silenced O6-methylguanine-DNA-methyltransferase
(MGMT) gene [6]. In children, hypermethylated MGMT promoter
predicts for response to alkylating agents [7], however the survival
of children treated with adjuvant temozolomide does not appear to
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be improved when compared with historical controls [8–11].
Similarly, the disappointing results obtained in early phase clinical
trials by the use of inhibitors directed against EGFR [12] and
PDGFR [13] are likely in part due to inadequate patient selection,
although as yet there are no validated markers predictive of
response in high grade gliomas, and it is unclear whether there are
differences in the paediatric setting.
The mechanisms of drug resistance in paediatric high grade
glioma are poorly understood, in part due to the limited availability
of suitable models of the disease. Nearly all preclinical and functional
work is carried out in a relatively small panel of adult glioblastoma
cell lines in vitro, and it is currently unclear how representative these
are of the underlying biology of paediatric lesions.
In order to begin to address these questions, we have carried out
a detailed molecular and phenotypic characterisation of a series of
paediatric high grade glioma cell lines in comparison to routinely
used adult lines. Through an integrated profiling approach, we
demonstrate that glioma cell lines derived from paediatric patients
show key molecular differences to those from adults, some of
which are well known, whilst others may provide novel targets for
evaluation in primary tumours. We thus provide the rationale for
using paediatric high grade glioma cell lines for preclinical and
mechanistic studies.
Materials and Methods
Cell culture
Adult glioblastoma cell lines, A172, LN229, SF268, U87MG,
U118MG and U138MG were obtained from ATCC (LGC
Promochem, Middlesex, UK). Paediatric glioblastoma KNS42
cells were obtained from the JCRB (Japan Cancer Research
Resources) cell bank. Paediatric SF188 cells were kindly provided
by Dr Daphne Haas-Kogan (UCSF, San Francisco, CA, USA),
whilst UW479, Res259 and Res186 were kindly provided by Dr
Michael Bobola (University of Washington, Seattle, WA, USA).
They were grown as monolayers in DMEM/F12 Ham’s
medium+10% FCS in 5% CO2.
Immunohistochemistry
Cells were grown to 70–80% confluency in chambered slides
(Nunc, Rochester, NY, USA) fixed in either 4% paraformalde-
hyde:0.5% TritonX-100 in PBS (GFAP, synaptophysin, vimentin,
nestin and CD133) or ice cold methanol (S100). The cells underwent
a peroxidase block (Dako, Ely, UK) followed by washes in
0.05%Tween in TBS prior to incubation with primary antibody –
GFAP (clone 6F2, 1:50 dilution, Dako); synaptophysin (SY38, 1:10,
Dako); vimentin (V9, 1:100, Dako), S100 (B32.1, 1:20, Abcam,
Cambridge, UK), nestin (10C2, 1:400, Miltenyi Biotech, Bergisch
Gladbach, Germany), or CD133 (W6B3C1), 1:40, Miltenyi Biotech).
Staining was visualised by the Envision horseradish peroxidase
system (Dako) according to the manufacturer’s instructions.
Genomic analysis
500 ng of DNA was analysed on the Affymetrix GeneChip
Human Mapping 250K Nsp and Sty arrays by the UCL Institute
of Child Health Gene Microarray Centre, according to the
manufacturer’s protocol. The raw data were processed and
genotypes called using the BRLMM method of the Affymetrix
GTYPE package. Copy number ratios were calculated by the
Affymetrix CNAT 4 algorithm, using quantile normalisation and a
Gaussian smoothing bandwidth of 0.1 Mb. Normal references
were provided by public data from an unmatched panel of 30
Caucasian female DNA samples, the Centre d’Etude du
Polymorphisme Humain (CEPH) trio mothers, analysed on the
same platform by The International HapMap Consortium
(International HapMap Consortium 2007, http://www.hapmap.
org). The copy number data set was compared to the positions of
known copy number variations (CNVs) in the HapMap popula-
tions displayed on the UCSC genome browser and any copy
number changes in the current data that overlapped with these
CNVs were noted. LOH was inferred using the linkage
disequilibrium Hidden Markov Model as implemented in dChip
(http://www.dchip.org). False positives were reduced by excluding
apparent LOH regions present in more than 10% of all 60 CEPH
trio parents. LOH was taken as copy neutral if the copy number
measured by dChip was close to diploid (1.7–2.3 copies). All data
have been submitted according to MIAME guidelines [14] to the
public data repository ArrayExpress (http://www.ebi.ac.uk/
arrayexpress/) with accession number E-TABM-579.
Multiplex fluorescence in situ hybridisation (M-FISH) analysis
was performed on metaphase spreads prepared from Res259 cells
using a Vysis SpectraVysion probe (Abbot Molecular, Abbott
Park, IL, USA) following the manufacturer’s instructions as
previously described [15]. Images were captured using a Zeiss
Axiophot microscope equipped for epifluorescence using cooled
CCD-camera (Hamamatsu, Welwyn Garden City, UK). Image
analysis was performed using SmartCapture X software (Digital
Scientific, Cambridge, UK).
Fluorescent in situ hybridisation (FISH)
FISH analysis was carried out on metaphase chromosome
preparations as previously described [16]. Probes directed against
CDK4 (RP11-66N19,RP11-571M6), PDGFRA (RP11-231C18,
RP11-626H4, RP11-117E8), and PTEN (RP11-105A10) were
labelled with Cy5 (GE Healthcare, Amersham, UK), whilst
commercial probes against RB1 (Abbot Molecular) and
CDKN2A/B (Abbott Molecular) were SpectrumOrange-labelled.
Appropriate centromeric probes were labelled with either
fluorescein or SpectrumGreen. Hybridised preparations counter-
stained with DAPI in antifade (Vector Laboratories Inc.,
Burlingame, CA, USA). Images were captured using a cooled
charge-coupled device camera (Photometrics, Tuscon, AZ, USA).
Methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA)
Promoter methylation was assessed by kits ME001, ME002 and
ME011 according to manufacturer’s instructions (MRC-Holland,
Amsterdam, Netherlands) [17]. Briefly, 100 ng of tumour DNA
was denatured in 5 mL of Ultra-Pure Water at 98uC for 5 min and
then incubated with the probe mix for 20 h at 60uC. After probe
hybridization, each sample was divided into two different tubes.
Half of the sample was ligated using a ligase enzyme and in the
other half ligation was combined with HhaI digestion resulting in
ligation of the methylated sequences only. The resulting products
were amplified by PCR using a FAM-labeled primer, following
manufacturer’s instructions. PCR products were analyzed on ABI
Prism 310 single capillary genetic analyzer (Applied Biosystems)
using the GeneScan 3.7 software (Applied Biosystems). Duplicate
experiments were performed for methylation analysis and average
ratios were calculated. We interpreted ratios as absence of
hypermethylation (0.00–0.24), mild hypermethylation (0.25–
0.49), moderate hypermethylation (0.50–0.74), and extensive
hypermethylation ($0.75), as previously described [18].
Western blot analysis
Cells at 80% confluence were trypsinised, washed with PBS and
lysed for 1 hr at 4uC in lysis buffer (Cell Signaling, Hertfordshire,
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UK) and a complete mini protease inhibitor cocktail (Roche
Diagnostics, Mannheim, Germany). Cells were then centrifuged
at 11,000 rpm at 4uC for 15 min, and protein concentration
determined (Pierce BCA assay, Rockford, IL, USA). Total
protein extracts (30 mg/lane) were separated electrophoretically
in 4–20% SDS-polyacrylamide gel and transferred to nitrocel-
lulose membranes (Invitrogen Ltd, Paisley, UK). Immunodetec-
tion was performed using antibodies against cRAF (1:500, Santa
Cruz Biotechnologies, Santa Cruz, CA, USA), phosphorylated
and total Erk1/2, Akt, GSK3b and S6 (all 1:1000, Cell
Signaling), and GAPDH (1:2000, Chemicon, Hampshire, UK).
Blots were revealed with peroxidase-conjugated secondary anti-
rabbit or anti-mouse antibodies (GE Healthcare, Amersham,
UK) followed by ECL chemiluminescence solution (GE
Healthcare).
mRNA expression profiling
10 mg of total RNA was used to generate labelled cRNA and
hybridised to U133Plus 2.0 oligonucleotide arrays (Affymetrix,
Santa Clara, CA, USA) containing more than 40,000 transcripts
by the UCL Institute of Child Health Gene Microarray Centre
according to standard manufacturer protocols. Probe intensity
data for each array was normalized to a baseline array with
median signal intensity using the ‘‘invariant set’’ model. Model-
based expression was performed using the perfect-match/
mismatch (PM/MM) model to summarize signal intensities for
each probe set. All data have been submitted according to
MIAME guidelines [14] to the public data repository ArrayEx-
press (http://www.ebi.ac.uk/arrayexpress/) with accession num-
ber E-TABM-579. For the supervised identification of genes
exhibiting differential expression between paediatric and adult
high grade cell lines, expression values were subjected to a
variation filter to exclude probe sets with minimal variation
across the samples, and an absolute signal to noise metric of
greater than 1.5 was subsequently used to identify marker probe
sets using GenePattern software (http://www.broad.mit.edu/
cancer/software/genepattern/);. Differentially expressed co-ordi-
nate sets of genes were identified using Gene Set Enrichment
Analysis (GSEA, www.broad.mit.edu/gsea/) with a nominal p
value cut-off of 0.001.
Real-time quantitative RT-PCR
cDNA was prepared from 1 mg of tumour or reference RNA by
random primed reverse transcription using Superscript II
(Invitrogen, Paisley, UK). TaqManH Gene Expression Assays
were obtained from Applied Biosystems (Warrington, UK) for
LYN (Hs00176719), CRKL (Hs00178304), AXL (Hs00242357)
and EPHA6 (Hs00297133). PCRs were performed in a 10 ml
reaction volume containing 5 ml 26 buffer/enzyme mix, 0.5 ml
206assay mix, 0.5 ml 206GAPDH endogenous control assay mix
(Hs99999905) and 1 ml input cDNA. Assays were run on an
Applied Biosystems 7900 Sequence Detection System and results
analysed by the standard curve method. Data were normalised to
Universal Human Reference RNA (Stratagene, La Jolla, Califor-
nia, USA).
Results
Paediatric glioma cell lines grown as monolayers in vitro
express astrocytic and stem cell markers
All paediatric glioma cell lines were derived from astrocytomas
of differing grades arising in patients aged 3–16 years old. They
were established in vitro as monolayer cultures, with doubling times
of between 24–48 hours, and demonstrated a mixture of stellate
and bipolar morphologies, with some cells of polygonal, cuboidal
or flattened appearance (Table 1). The astrocytic nature of the
cells was confirmed in culture by immunohistochemistry with a
range of glial markers (Figure 1). All cells showed some degree of
GFAP-positivity, although SF188 and Res259 were only weakly
expressing. All cells were strongly positive for S100 and vimentin,
with the exception of UW479, which was vimentin negative.
There was little synaptophysin expression, save for the occasional
isolated cell in SF188 and KNS42 cultures. There was a
surprisingly high level of expression of stem cell markers in the
paediatric glioblastoma lines, with both SF188 and KNS42
strongly positive for nestin, and containing 7% and 4% CD133-
positive cells respectively.
Genomic profiling reveals numerous chromosomal
abnormalities and focal amplifications/deletions
Affymetrix 500K SNP array analysis revealed all paediatric
glioma cell lines to display complex genomes with numerous gross
chromosomal copy number abnormalities and rearrangements.
After exclusion of known copy number variants, this high-
resolution copy number profiling additionally highlighted a
number of focal copy number aberrations, which were confirmed
by FISH on metaphase preparations (Figure 2). The glioblastoma
cell line SF188 harboured high-level amplifications of several
oncogenes known to be present in paediatric glioblastoma tumour
samples. These included MYC at 8q24, CCND1 at 11q13, CDK4 at
12q14, all of which were due to extrachromosomal double minute
formation, and overexpression of the corresponding proteins was
Table 1. Characteristics and immunophenotype of paediatric glioma cells grown as monolayers.
Cell
line
WHO
grade Diagnosis Age Sex Morphology
Doubling
time Immunohistochemistry
GFAP S100 Vimentin
Synapto-
physin Nestin CD133
SF188 IV Glioblastoma multiforme 8 yrs male stellate, polygonal, bipolar 26 hrs ++ ++ +++ ++ 7%
KNS42 IV Glioblastoma multiforme 16 yrs male cuboidal, polygonal, bipolar 48 hrs +++ +++ +++ ++ 4%
UW479 III Anaplastic astrocytoma 13 yrs female polygonal, stellate 28 hrs +++ +++ 2 + 1%
Res259 II Diffuse astrocytoma 4 yrs female polygonal, cuboidal, bipolar 24 hrs + ++ +++ 2 0%
Res186 I Pilocytic astrocytoma 3 yrs female stellate, flattened, bipolar 46 hrs +++ ++ +++ 2 0.1%
The astrocytic nature of the cells was confirmed in culture by immunohistochemistry with a range of glial and stem cell markers. (+++) strongly positive; (++) moderately
positive; (+) weakly positive; (2) negative.
doi:10.1371/journal.pone.0005209.t001
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confirmed by Western blotting (data not shown). There was
furthermore a focal deletion of NF1 at 17q11.2. KNS42
glioblastoma cells, by contrast, contained no genuine amplifica-
tions, but instead its highly rearranged genome harboured low-
level copy number gains at loci such as 3q26 (PIK3CA), and
hemizygous deletions at known tumour suppressor loci such as
13q14 (RB1). FISH analysis confirmed that this was due to the loss
of a single copy from an otherwise triploid genome. Homozygous
deletion at the CDKN2A/B locus at 9p12 was observed in the
anaplastic astrocytoma UW479 line, which additionally harboured
numerous high level copy number changes including 3p11-p12,
6p21, 18p11 and 19q12. CDKN2A/B deletion was also observed in
Res259 astrocytoma cells, which also contained the well-described
4q12 amplicon, resulting in high level gains of the oncogenes
PDGFRA and KIT, and low-level gain of a region including KDR/
VEGFR2. This was found from FISH and M-FISH analysis to be
due to an unbalanced translocation between chromosomes 4 and
19, resulting in a der(19)t(4;19). Finally, Res186, originally derived
from a pilocytic astrocytoma, harboured the least complex
genomic profile, although was found to have an intragenic
homozygous deletion of PTEN at 10q23.
Copy neutral and epigenetic events in paediatric high
grade glioma cells
In addition to the copy number changes, we also observed
several copy neutral loss of heterozygosity (LOH) events (Figure 2).
KNS42 cells exhibited focal copy neutral LOH at 19p13 (KLF2)
and 21q21 (HEMK2), whilst larger regions were observed in
UW479 cells at chromosome 2q11-qter and in Res186 at 7p11-
pter and 17p13 (TP53). Although the significance of these events is
not clear, it is expected that such loci may harbour genes in which
the remaining allele may harbour a point mutation, as is the case
for TP53.
In order to explore epigenetic events in these lines we carried
out methylation-specific multiplex ligation-dependent probe
amplification (MS-MLPA) on 39 genes known to be hypermethy-
lated at CpG islands in human cancer. Certain genes such as
RASSF1A and ASC were found to be methylated in all cell lines
tested (Table 2). There was specific promoter hypermethylation in
FHIT in SF188 and Res259, HIC1 in Res259 and TP73 in Res186
cells. Interestingly, UW479 additionally harboured extensive
promoter hypermethylation at a host of genes assayed including
APC, CASP8, CD44, CDH13, CHFR, ESR1, GSTP1, IGSF4,
MGMT, PAX5A, PAX6, and RARB. Of direct relevance to clinical
resistance to alkylating agents were the observations of methyla-
tion in the mismatch repair gene MLH3 in Res259 cells, which
also harboured high levels of promoter hypermethylation of
MGMT, along with KNS42 cells. Low to moderate MGMT
methylation was also observed in UW479 and Res186 cells.
Differential constitutive activation of PI3K, MAPK and
downstream pathways
Protein expression was measured by Western blot to examine
constitutive pathway activation of several key signalling transduc-
tion networks of importance in gliomagenesis (Figure 3). There
was a modest activation of the MAPK pathway as determined by
levels of phosphorylated Erk 1/2 in the paediatric high grade lines
SF188 and UW479 as compared to KNS42 and the low grade
lines (Res259, Res186). Although Akt pathway activation was seen
in all paediatric cells, this was considerably lower than that
observed in our panel of adult glioblastoma lines, except in the
PTEN null line Res186, which showed high levels of phospho-Akt.
Phosphorylated GSK3b levels were low in UW479, Res259 and
Res186, and almost entirely absent in the glioblastoma lines SF188
and KNS42. Although there was some degree of ribosomal protein
Figure 1. Immunophenotyping of paediatric glioma cell lines. All lines were grown as monolayers and stained with a variety of glial and stem
cell markers including glial fibrillary acidic protein (GFAP), S100, vimentin, synaptophysin, nestin and CD133. H&E – haematoxylin and eosin. All
images original magnification 6400.
doi:10.1371/journal.pone.0005209.g001
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S6 activation in all lines, this was particularly pronounced in
KNS42 and Res259, with very high levels of phospho-S6. Taken
together, although variable, we observed constitutive activation of
one or more of these signal transduction pathways in all the
paediatric glioma lines.
Expression signatures of functionally relevant genes
distinguishes between high grade paediatric and adult
glioma cell lines
In order to investigate the differences between the paediatric-
and adult-derived cell lines at the gene expression level, we carried
out expression profiling using Affymetrix U133 Plus2.0 arrays. For
the comparison, we excluded the lines Res259 and Res186,
derived from low-grade tumours, in order to avoid the possible
Table 2. Methylation-specific multiplex ligation-dependent
probe amplification of 39 genes in paediatric glioma cell lines.
Gene SF188 KNS42 UW479 Res259 Res186
ASC 52% 66% 52% 81% 100%
APC 2% 2% 100% 1% 2%
ATM 0% 2% 1% 1% 0%
BRCA1 1% 1% 2% 3% 3%
BRCA2 0% 0% 0% 0% 0%
CASP8 1% 3% 71% 1% 3%
CD44 0% 2% 48% 1% 0%
CDH13 2% 24% 94% 4% 0%
CDKN1B 0% 0% 0% 0% 0%
CDKN2A 2% 1% DEL DEL 3%
CDKN2B 3% 4% DEL DEL 4%
CHFR 0% 1% 81% 0% 0%
DAPK1 5% 0% 0% 0% 0%
ESR1 25% 51% 31% 74% 55%
FHIT 62% 0% 0% 56% 2%
GATA5 10% 0% 14% 86% 94%
GSTP1 3% 5% 75% 0% 70%
HIC1 2% 2% 7% 92% 0%
IGSF4 0% 0% 44% 0% 0%
MGMT 11% 79% 26% 63% 57%
MLH1 1% 1% 1% 1% 2%
MLH3 0% 0% 0% 70% 0%
MSH2 0% 0% 0% 0% 0%
MSH3 0% 0% 3% 5% 7%
MSH6 0% 0% 0% 7% 0%
PAX5A 43% 46% 99% 53% 100%
PAX6 0% 0% 100% 0% 0%
PMS2 0% 0% 3% 3% 0%
PTEN 4% 1% 1% 2% DEL
RARB 5% 4% 56% 2% 0%
RB1 5% 0% 0% 0% 23%
RASSF1A 95% 90% 100% 100% 100%
STK11 0% 2% 0% 0% 0%
THBS1 5% 9% 9% 10% 0%
TIMP3 0% 16% 0% 1% 2%
TP53 1% 4% 3% 1% 22%
TP73 0% 0% 0% 0% 43%
VHL 0% 0% 0% 0% 0%
WT1 0% 88% 7% 69% 21%
Values give percentage methylation at CpG islands in the genes promoter.
DEL = gene deletion. n.d = not done.
doi:10.1371/journal.pone.0005209.t002
Figure 3. Constitutive activation of key signalling pathways in
glioma cell lines. Western blots analysis of c-Raf, phospho/total Erk1/
2, phospho/total Akt, phospho/total GSK3b, phospho/total S6 and
GAPDH as loading control in adult (LN229, A172, U118MG, U138MG,
U87MG, SF268) and paediatric (SF188, KNS42, UW479, Res259, Res186)
glioma cell lines.
doi:10.1371/journal.pone.0005209.g003
Figure 2. Genomic profiling of paediatric glioma cell lines. Copy number and loss of heterozygosity (LOH) profiles were generated by
Affymetrix 500K SNP arrays. Log2 ratios are plotted (y axis) for each probeset according to chromosomal location (x axis). Loss (blue) and retention
(yellow) of heterozygosity is depicted in the lower portion of the plots. Fluorescent in situ hybridisation validation of selected copy number changes is
represented with clones for CDK4, RB1, CDKN2A/B, PDGFRA and PTEN (lCy5/SpectrumOrange) and appropriate centromeres (fluorescein/
SpectrumGreen).
doi:10.1371/journal.pone.0005209.g002
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confounding factors of grade. Despite the small number of lines
profiled, we were able to identify 93 genes significantly
differentially expressed between paediatric and adult high grade
glioma cell lines (Figure 4A). The differentially expressed genes
included several kinases which were validated by quantitative real-
time RT-PCR (Figure 4B). These included members of the Src
family kinases - LYN and the adaptor molecule CRKL, highly
expressed in paediatric lines, along with SRC itself and also YES1.
Also upregulated in the paediatric vs adult lines were several early
response genes including FOS and FOSB. Highly expressed in the
adult lines were the receptor tyrosine kinases EPHA6 and AXL,
and also CDK9 and ILK.
In addition, gene set enrichment analysis (GSEA) highlighted
co-ordinated differentially high expression of several gene lists
associated with maintenance of DNA replication and repair in
paediatric vs adult cell lines (MORF_MSH2, GNF2_MLH1,
GCM_RAD21, DNA_replication_reactome) (Figure 4C). Further-
more, gene sets representing co-ordinated regulation of extracel-
lular matrix protein in response to cytokines were found enriched
in the adult compared to the paediatric lines (IL6_SCAR_-
FIBRO_UP, CROONQUIST_IL6_RAS_UP, TGFBETA_-
C1_UP). Although the nominal p values of these analyses was
less than 0.001, q values for estimates of the false discovery rate
were all greater than 0.9, presumably due to the small sample size.
Discussion
Understanding and exploiting the similarities and differences
between adult and paediatric gliomas is an important strategy for
the development of new targeted therapies. The intrinsic drug
resistance of high grade gliomas represents a major challenge in
the clinical management of children with the disease, and efforts to
Figure 4. Expression profiling of paediatric and adult glioblastoma cell lines. (A) Heatmap demonstrating hierarchical clustering of 93
differentially expressed genes between paediatric (SF188, KNS42, UW479) and adult (LN229, A172, U118MG, U87MG, SF268) high grade glioma cell
lines. (B) Quantitative real-time (TaqMan) RT-PCR confirming differential expression of CRKL, LYN, EPHA6 and AXL. Expression values are plotted
relative to Universal Human Reference RNA. (C) Gene Set Enrichment Analysis highlighting co-ordinated differential expression of gene sets defined a
priori. Enriched in paediatric high grade glioma cell lines - MORF_MSH2, GNF2_MLH1, GCM_RAD21, DNA_replication_reactome; enriched in adult
lines IL6_SCAR_FIBRO_UP, CROONQUIST_IL6_RAS_UP, TGFBETA_C1_UP. Nominal p value,0.001.
doi:10.1371/journal.pone.0005209.g004
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understand and overcome this are hampered by a lack of
mechanistic data in paediatric glioma models. We have sought
to address this by collecting and carrying out a detailed molecular
and phenotypic characterisation of the few available paediatric
glioma cell lines, with a view to incorporating them into ongoing
drug development programmes.
There is an acute clinical need to develop better treatment
strategies for the refractory high grade gliomas in childhood, and
having lines representative of paediatric glioblastoma (WHO
grade IV – SF188 and KNS42) and anaplastic astrocytoma (WHO
grade III – UW479), would be extremely useful in preclinical and
mechanistic studies of the disease. These lines all grew as either
stellate or bipolar cells, with some polygonal features, in
monolayers, and the immunophenotypes were representative of
high grade glial tumours, including expression GFAP, S100 and
vimentin. There were slight discrepancies with a previous
publication referring to some of these lines [19], with a greater
degree of S100 staining in UW479, and less GFAP in Res259 in
our study, however it unclear whether this is reflective of
methodological differences, culture conditions or changes in gene
expression over time.
It is of considerable interest to note the relative high levels of
CD133 positive cells in both SF188 (7%) and KNS42 (4%).
Intrinsic drug resistance in the proportion of clinical glioblastomas
comprised of tumour stem cells has been suggested to play a key
role in drug resistance in this disease, and the high CD133-positive
content of these cells grown as monolayers may make them
particularly relevant in preclinical drug screening programmes.
All three high grade lines had highly complex genomic profiles
and harboured amplifications and deletions at several known
cancer genes dysregulated in paediatric glioma, including CCND1,
MYC, CDK4, PIK3CA, CDKN2A/B, and RB1 [2,20–23]. Although
there are no molecular alterations yet described that are diagnostic
for paediatric high grade glioma, these genes cover a broad
spectrum of reported genomic aberrations. In addition, large scale
chromosomal imbalances such as gain of chromosomes 1q and 7,
and losses of 10q and 13q, reported at high frequencies in primary
tumours [24], are present within these cell lines.
There were contrasting genomic profiles in the two paediatric
glioblastoma lines. SF188 harboured an amplifier phenotype, with
coordinated amplification of CCND1 and CDK4 evidence of a lack
of cell cycle control by virtue of dysregulation of the RB1 pathway.
By contrast, KNS42 cells achieved a similar end through direct
deletion of RB1 itself. No RB1 hypermethylation was detected.
Simultaneous abrogation of core signalling pathways in glioblas-
tomas, as recently reported for primary tumours [25,26], are in
evidence in both these cell lines, with further disruption to the p53
pathway (through point mutations of TP53 in both lines), and the
RTK/PI3K/AKT pathway via NF1 deletion in SF188 and
PIK3CA copy number gain in KNS42.
Interestingly, UW479 cells, as well as harbouring numerous
high level amplifications, also had extensive promoter hyper-
methylation at a variety of epigenetically regulated genes,
including APC, CASP8, CD44, CDH13, CHFR, ESR1, GSTP1,
IGSF4, MGMT, PAX5A, PAX6, and RARB. They also had, in
common with all the lines tested, methylated RASSF1A and TMS1
genes. RASSF1A promoter methylation is one of the most common
molecular changes in cancer, and may modulate multiple
apoptotic and cell cycle checkpoint pathways [27]. TMS1/ASC is
an intracellular signaling molecule with proposed roles in the
regulation of apoptosis, nuclear factor-kB activation, and cytokine
maturation, and has been found to be hypermethylated in
approximately 40% of adult glioblastoma cell lines and tumours
[28].
Of potential significance in preclinical drug screening was the
observation that UW479 and Res186 cells to harbour methylated
GSTP1. Glutathione-S-transferase p acts to enzymatically conju-
gate glutathione to the reactive metabolites of alkylating agents,
and up-regulation in glioblastoma tumour specimens has been
correlated with resistance to BCNU [29]. Of further direct
translational relevance was the observation that KNS42 cells were
found to have methylation in the MGMT promoter, but counter to
the expectation in glioblastoma cells, this did not confer a
sensitivity to in vitro treatment with the alkylating agent
temozolomide [30].
Two of the cell lines (Res259 and Res186) were reported to be
diffuse astrocytoma (WHO grade II) and pilocytic astrocytoma
(WHO grade I), which would make them extremely valuable in
vitro models. Due to the difficulty in culturing these lesions
successfully, and the relatively stable genomes reported in the
human disease [31–33], it is likely that these lines may have
acquired genetic alterations in culture. Interestingly, both lines
harboured genetic alterations reminiscent of high grade gliomas in
humans - including the archetypal 4q12 amplification spanning
PDGFRA and KIT in Res259, and PTEN deletion in Res186.
Despite this, their immunophenotypes more closely resembled low
grade lesions, with an absence of synaptophysin expression, in
contrast to the occasional positive cells seen in the high grade lines,
and higher grade tumours in humans [34]. Whether or not they
are truly reflective of the lesion from which they were derived, they
are likely to make excellent models for the study of specific
pathway modulation, i.e. that of the receptor tyrosine kinase and
PI3K/PTEN systems. This is of particular importance, as the
paediatric high grade lines were all PTEN wild-type, and there was
significantly lower constitutive levels of phosphorylated Akt in
these cells than a selection of the commonly used adult
glioblastoma lines.
Similarly, constitutive activation of additional key signalling
pathways would further increase the usefulness of the cell line
panel for drug development. The MAPK pathway is represented
in the KNS42 glioblastoma cells, which otherwise has little
constitutive activation of Akt. High levels of phosphorylated S6 in
both KNS42 and Res259 cells shows a significant activation of the
mTOR pathway, potentially independent of upstream PI3K/Akt
signalling. mTOR is emerging as a therapeutic target in human
gliomas [35], and extending this to the paediatric setting will be
facilitated by the use of these models for screening mTOR
inhibitors, alone and in combination strategies.
Global measures of gene expression also served to highlight the
differing genetic background of the paediatric lines. The
differential expression of diverse kinases including LYN, CRKL,
EPHA6 and AXL between the high grade glioma cells derived from
patients of different ages suggests a number of potential new drug
targets, and provides impetus for molecular pathology investiga-
tions to confirm their presence in vivo. Two such observations are
the overrepresentation of genes associated with DNA integrity in
the paediatric cells, and underrepresentation of those associated
with the immune response. As both of these areas are under
intense research for the development of novel therapeutic agents in
gliomas [36–40], measurement of the specific elements responsible
for their modulation is needed in order to ensure the most
appropriate model is utilised for mechanistic and preclinical
assessment.
The paediatric lines have already proven their usefulness in vitro
with studies identifying differential drug sensitivity and mecha-
nisms of action/resistance [19,30,41,42]. As an adjunct to this, we
are currently establishing and profiling them as in vitro neurosphere
cultures, and in vivo as xenografts in immunodeprived mice. It is
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clear, however, that to fully represent the heterogeneity present in
human glioma [25], and particularly those derived from children,
additional well-characterised models will be required if we are to
reliably test novel agents aimed at treating these diverse, clinically
refractory tumours.
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